Related Experiment Video

Updated: May 5, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K

Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells

Kai Wu, Qingshan Chang, Yongju Lu

    Oncotarget
    |November 28, 2013
    PubMed

    Insights

    Drug resistance in lung cancer involves STAT3 activation, which boosts Akt signaling and reduces EGFR TKI effectiveness. Targeting both EGFR and STAT3 may overcome this resistance and improve treatment outcomes.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Research

    Background:

    • Hyperactivation of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase drives lung cancer.
    • EGFR tyrosine kinase inhibitors (TKIs) like gefitinib initially control tumor growth but often face drug resistance.
    • Understanding resistance mechanisms is crucial for improving lung cancer therapy.

    Purpose of the Study:

    • To investigate the mechanism of gefitinib resistance in lung cancer.
    • To identify novel therapeutic targets for overcoming EGFR TKI resistance.
    • To explore the role of STAT3 and Akt signaling in EGFR TKI efficacy.

    Main Methods:

    • Investigated the interaction between EGFR, STAT3, and SOCS3 in response to gefitinib.
    • Assessed the impact of STAT3 activation on Akt signaling pathways.
    • Utilized genetic and pharmacological inhibition of STAT3 in combination with gefitinib.
    • Evaluated tumor cell growth in response to combined therapeutic strategies.

    Main Results:

    • Gefitinib treatment increased the association of EGFR with STAT3, leading to STAT3 de-repression from SOCS3.
    • De-repressed STAT3 promoted Akt activation, contributing to gefitinib resistance.
    • Inhibition of STAT3 abrogated Akt activation and sensitized resistant cells to gefitinib.
    • Combined gefitinib and STAT3 inhibition synergistically reduced tumor cell growth.

    Conclusions:

    • STAT3 activation is an intrinsic mechanism of drug resistance to EGFR TKIs in lung cancer.
    • STAT3-dependent Akt activation impairs gefitinib efficacy.
    • Combinational targeting of EGFR and STAT3 presents a promising strategy to enhance TKI therapy in lung cancer.

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    8.0K
    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    7.6K

    Related Concept Videos

    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    5.2K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.6K
    The JAK-STAT Signaling Pathway01:20

    The JAK-STAT Signaling Pathway

    Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
    10.2K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    6.4K
    Intracellular Signaling Affects Focal Adhesions01:17

    Intracellular Signaling Affects Focal Adhesions

    Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
    Some...
    2.8K